Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions

In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:Selecting immuno-oncology vs targeted therapy in MSI-high cancers with co-occurring alterations (eg, BRCA, HER2, BRAF, NTRK)Switching to a new immuno-oncology strategy at progression on first-line immune checkpoint inhibitionNeoadjuvant treatment with immune checkpoint inhibitorsFinancial considerations when selecting chemotherapy vs immuno-oncologyPresenters:John L. Marshall, MDChief, Division of Hematology/OncologyDepartment of MedicineGeorgetown University HospitalWashington, DCJamie E. Chaft, MDAssociate Attending PhysicianThoracic Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New YorkScot Niglio, MDMedical OncologistBethesda, MarylandContent based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.Link to full program:https://bit.ly/31vQtqb

There are no comments yet.

Please log in to write the first comment.